Skip to main content

Advertisement

Fig. 2 | BMC Cancer

Fig. 2

From: Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme

Fig. 2

a Illustaration of the experimental workflow. b Bar plot of gene expression levels of PD-L1 in three different cell-lines. Cell treatment condition and cell type is displayed at the bottom. c Gene expression heatmap of all experimental conditions with five biological replications and three cell lines. Arrows mark the direction of samples and genes. High and low gene expression levels of the JAK/STAT pathway panel is displayed in red and green color, respectively. Cell treatment condition and cell type is displayed at the bottom. c Immunoblot of all cell lines and experimental conditions. Actine was used as loading control. d Immunostaining of PD-L1 in GSC 168 cell lines (proneural). In the upper panel, PD-L1 is shown and a quantification is given on the right side (f). In the bottom panel, PD-L1 is merged with ATPase (marks cell membrane) and DAPI (marks nucleoli). g In the upper panel, STAT3 phosphorylation is displayed within each experimental condition. High resolution images of TMZ and TMZ plus IFNγ are shown in the bottom panel. A quantification of the STAT3 phosphorylation level is given in (f). h Gene expression heatmap of the JAK/STAT pathway in de-novo and recurrent GBM (upper plot) combined with the STAT3 phosphorylation and PD-L1 protein levels. High and low gene expression levels of the JAK/STAT pathway panel are displayed in red and green color, respectively. i Immunoblots of 4 patients with primary and recurrent GBM selected because of exceptionally high PD-L1 levels in de-novo tumor tissue. Significance level is displayed as following: * p < 0.05, ** p < 0.01, *** p < 0.001

Back to article page